Furthermore, hepatocyte specific deletion of CB1 or administration of a non-brain-penetrant CB1 antagonist prevents hepatic steatosis, hyperlipidemia, and insulin resistance on a high-fat diet, independent of weight gain [21], [22]. Here, CNR1 is linked to Hepatic steatosis.